Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Neuropharmacology. 2017 Sep 1;134(Pt B):310–322. doi: 10.1016/j.neuropharm.2017.08.036

Table 2.

Select ongoing clinical trials

Study phase Mode of delivery Cell type Time from onset Primary Outcome measure Secondary Outcome measure Clinical identifier
I IC CTX0E03 neural stem 6 mo–5 year safety Function outcome NCT01151124
I/II IC Modified stem, SB623 6–12 mo safety Function outcome NCT01287936
II IC Autologous peripheral CD34+ stem >6 mo, <60 mo Function outcome Function outcome; Imaging NCT00950521
I IV; IT Umbilical cord, mesenchymal IV, 7–14 d; IT, Function outcome Function outcome; MRI changes NCT01389453
I/IIa IV Autologous bone marrow mononuclear 24–72 h Safety; Feasibility Function outcome NCT00859014
I/IIa IV Autologous mesenchymal stem Within 6 wk Safety; Feasibility Function outcome NCT00875654
I/II IA Autologous bone marrow CD 34 + stem 7 d safety Function outcome NCT00535197

Abbreviations: IA=intra-arterial; IC=intracerebral; IT=intrathecal.